Oxytocin shows why residue sequence alone may be incomplete for a cyclic research peptide. The structure includes a connection between residues and a terminal feature that should remain explicit. A procurement record must keep those covalent details separate from the offered chemical form, nominal amount and analytical evidence for the supplied sample.
Keep the sequence and connection together
The NLM MeSH oxytocin entry gives Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 and a cyclic 1–6 disulfide. This is a reference identity, not a supplier certificate. Record both the residue string and the Cys1–Cys6 connection. A sequence-only line can omit topology; the buyer should not leave that omission for someone else to interpret during quotation or receipt.
Distinguish terminal amide from supplied salt
The NH2 at the C terminus describes a covalent terminal feature. A chemical-form or counterion designation is a separate field. The linked catalog route uses an acetate name, but the supplier should explain the actual offered form and quantity basis. Do not infer a measured composition from the URL. The table keeps sequence, connection, terminal feature and offered chemical form on independent lines so none disappears into a short title.
| Field | Reference feature | Supplier question |
|---|---|---|
| Sequence | Cys–Tyr–Ile–Gln–Asn–Cys–Pro–Leu–Gly | Same offered residue order? |
| Connection | Cys1–Cys6 disulfide | Evidence addresses requested topology? |
| C terminus | Gly-NH2 | Amide explicitly represented? |
| Chemical form | Separate supplied-form statement | What does acetate designate here? |
| Testing scope | Identity, amount and other requested tests | Which sample and methods are covered? |
Choose evidence for structure, not only mass
Ask what analytical scope supports the requested identity and disulfide requirement. A matching intact mass is not automatically a complete topology assessment. The laboratory reviewer should determine which characterization is needed for the intended project and whether the offered records address it. Request the named sample and lot mapping. Keep an illustrative reference report separate from the evidence for material that will actually be dispatched.
Review packaging claims as separate questions
A closed vial, white powder or research label does not establish sterility, endotoxin status or any medical suitability. If the project has microbiological requirements, specify the required evidence separately and ask whether it is available. Do not assume that a familiar peptide name supplies those requirements automatically. Similarly, preserve the distinction between nominal fill and measured content instead of converting a general purity percentage into a mass or concentration claim.
Preserve the agreed identity when alternatives appear
If a different connection, terminus, sequence or supplied form is proposed, request a marked alternative rather than accepting the same name as proof of equivalence. The final schedule should state the chosen identity, quantity basis, containers and analytical scope. On receipt, compare the delivered record with that schedule and leave gaps open for review. This article is limited to research-material specification and does not provide administration, dosing or clinical-use guidance.
Before closing this review
- Topology accompanies the residue string.
- Terminal amide is not a counterion field.
- Packaging is not sterility evidence.
- Proposed structural alternatives remain separate.
Continue with review the relevant catalog record; prepare a precise material inquiry. Save the relevant product or guide link alongside the written response so another reviewer can reconstruct the decision.
Editorial scope: research-material procurement and document review. Not medical guidance, dosing instructions or a claim of suitability for human use. Requirements and availability must be confirmed for the quoted material.
